Disease burden of pneumococcal diseases and economic evaluations of pnemcococcal conjugate vaccines

Project: Ministry of Health and WelfareMinistry of Health and Welfare Commission Research

Project Details


Vaccination is the front-line of epidemic prevention, posing a crucial influence on disease control. Mass vaccination not only provides direct effects that reduces disease incidence in those immunized but also protects the unvaccinated against infection, which is known as indirect effects or herd-immunity effects. Although vaccine effectiveness is a major concern, the limited government budget and medical resources remain important for the policy makers. Therefore, cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA) are commonly-used pharmacoeconomic methodologies to evaluate if a vaccination policy is feasible Not until October 2007, invasive pneumococcal disease (IPD) has been included as one of the notifiable infectious diseases for better disease surveillance. As the surveillance duration is still short, hence the national epidemiologic data are not readily stable. Besides, the medical, societal burden and economic evaluations after pneumococcal infections are still lakcking. In response to the aggressive propaganda of newly-lauched 7-valent, 10-valent, 13-valent and 23-valent pneumocccoal conjugate vaccines (PCV7、PCV10、PCV13、PPV23), epidemiological study and economic evaluations of those vaccines in Taiwan are urgently needed to order to facilitate the enaction of effective prevention measure against those diseases. This study have two research emphases: (1) to carry out medical and societal cost burden analysis due to pneumococcal infections via the results derived from the to-be-applied of National Health Insurance Research Database (NHIRD) to extract both epidemiological and cost parameters such as hospitalized cases, length fo stay in hospital, direct medical cost and indirect cost due to meningitis, pneumonia, bacteremia, and sepsis; (2) to develop Markov pharmacoeconomic model in order to conduct economic evaluation of various PCV’s. The methodology will be based on CEA, CUA, and CBA. To account for outcome uncertainty, one-way sensivity analysis and probabilisitc sensitivity analysis will be conducted.

Project IDs

Project ID:PG10101-0499
External Project ID:DOH101-DC-1007
Effective start/end date01/01/1231/12/12


  • Lung cancer
  • Chinese and western therapies
  • Matched Case-control study
  • Prognosis


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.